CLINICAL TRIALS PROFILE FOR ILOPERIDONE
✉ Email this page to a colleague
All Clinical Trials for Iloperidone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00254202 ↗ | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia | Completed | Vanda Pharmaceuticals | Phase 3 | 2005-11-01 | The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | GlaxoSmithKline | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | Massachusetts General Hospital | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT01207414 ↗ | Switching to Iloperidone From Other Antipsychotics in Schizophrenia | Completed | Novartis | Phase 4 | 2010-08-01 | Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons. |
| NCT01291511 ↗ | Relapse Prevention Study in Patients With Schizophrenia | Completed | Vanda Pharmaceuticals | Phase 3 | 2011-02-01 | The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia |
| NCT01348100 ↗ | Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients | Completed | Vanda Pharmaceuticals | Phase 1/Phase 2 | 2011-04-01 | This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen. In Phase A, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. In Phase B, the pharmacokinetic and safety profile of 2 depot clinical dosage forms will be compared, and 1 form will be selected for assessment in Phase C. Phase C of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies. |
| NCT01348100 ↗ | Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients | Completed | Novartis Pharmaceuticals | Phase 1/Phase 2 | 2011-04-01 | This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen. In Phase A, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. In Phase B, the pharmacokinetic and safety profile of 2 depot clinical dosage forms will be compared, and 1 form will be selected for assessment in Phase C. Phase C of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Iloperidone
Condition Name
Clinical Trial Locations for Iloperidone
Trials by Country
Clinical Trial Progress for Iloperidone
Clinical Trial Phase
Clinical Trial Sponsors for Iloperidone
Sponsor Name
